Oncoinvent ASA announces details of subsequent share offering
Oncoinvent ASA has announced a new share offering directed towards existing shareholders. The offering aims to rectify terms of a prior placement and retail sale.
Oncoinvent ASA has announced that it will conduct a subsequent share offering. The purpose of this offering is to provide existing shareholders with an opportunity to subscribe for new shares.
The company previously allocated 1,531,000 new shares in a private placement and 119,000 new shares in a retail offering. The subsequent offering will allow for the subscription of up to 200,000 new shares.
All new shares will be subscribed at the same price as in the earlier private placement and retail offering. The terms of the subsequent offering are subject to applicable securities law.
Oncoinvent ASA is a biotech company focused on cancer therapies. The company aims to develop new treatment options for cancer patients using its radioimmunotherapy platform.